Prospective Clinical Trial Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Prospective Clinical Trial

Health Care Term

A prospective clinical trial is a type of clinical research study in which patients are recruited and enrolled before any treatment is given. In this type of study, the patients are followed over time to evaluate the effectiveness and safety of a new intervention or treatment. The goal of a prospective clinical trial is to gather data that can be used to determine if a new treatment is safe and effective.

Healthcare industry uses prospective clinical trials to gather evidence and determine if a new treatment or intervention is safe and effective. The data generated from these trials is often used to support the development and approval of new drugs, devices, or treatments. Prospective clinical trials are considered the gold standard in clinical research, as they are rigorously designed and controlled to ensure that the results are reliable and unbiased.

Prospective clinical trials can be conducted in different phases, depending on the stage of development of the intervention being tested. Phase 1 trials are usually small and focused on safety, while phase 2 and 3 trials are larger and focus on efficacy and safety. Once a new intervention has been shown to be safe and effective in a prospective clinical trial, it may be approved by regulatory agencies and become available for use in clinical practice.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P